News Release Integra LifeSciences Reports Second Quarter 2025 Financial Results The Company reported GAAP gross margin of 50.4%, compared to 54.0% in the second quarter of 2024. Adjusted gross margin was 60.7%, compared to 65.2% in the prior year. Adjusted EBITDA for the second quarter of 2025 was $71.2 million, or 17.1$83.8 million, or 20.0% of revenue, in the prior year. The Company reported a GAAP net loss of $(484.1) million, or$(6.31) per diluted share, in the second quarter ...